Cinclus Pharma is a Swedish late-stage biopharmaceutical company committed to improving the medical outcome for patients suffering from severe stomach acid-related disorders. Cinclus Pharma’s lead candidate, Linaprazan glurate, holds the potential to decrease the unnecessary use of antibiotics, thereby reducing the development of antimicrobial resistance.
“Trill Impact Ventures has enabled us to formulate and focus our interest for impact and ESG topics into a clear, value creating strategy for improved quality of life for people worldwide living with gastric acid related diseases underpinned by our superior P-CAB, linaprazan glurate”
- Christer Ahlberg, CEO of Cinclus Pharma
Cinclus Pharma's solution
Unmet medical need in the treatment of gastroesophageal reflux disease. Currently, >20% of all patients are non-responsive to existing treatment options, resulting in suffering and reduced quality of life.
Increasing AMR: the eradication rate of H. pylori is decreasing globally due to increasing antibiotic resistance. H. pylori is included on WHO’s list of “high priority pathogens” as a bacterium that has the potential to pose a serious threat to public health.
Access gap to innovative medicines: For most innovative medicines, it takes years after market approval in high incomes countries until the product is introduced across low- and middle-income countries.
SDG # 3: Better health and well-being for all Potential contribution: Improving the standard of care in gastric acid related disease, and expanding geographic access outside high income countries
SDG # 3.3: Fighting communicable diseases Potential contribution: H. pylori eradication and combating antimicrobial resistance
SDG # 3.4: Reducing mortality from non-communicable diseases Potential contribution: H. pylori infection is the strongest known risk factor for development of gastric cancer